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Sub therapeutic rivaroxaban plasma concentrations following administration via 
Percutaneous Endoscopic Gastrostomy (PEG) feeding tubes – a note of caution 
 
Rosalind Byrne, Alison Brown, Jignesh P. Patel, Julia Czuprynska, Lara N. Roberts, Raj K. Patel, 
Roopen Arya 
  
Rivaroxaban is a direct factor Xa inhibitor currently licensed for the acute treatment and prevention of 
venous thromboembolism and for the prevention of stroke in the context of atrial fibrillation (AF). 
Rivaroxaban is rapidly absorbed with maximum concentrations reported around 2 - 4 hours post 
ingestion. Oral bioavailability is high (80 - 100%) for the 2.5mg and 10 mg tablet dose under fasting 
conditions or with food. The 20mg dose of rivaroxaban has reduced bioavailability of 66%, under 
fasting conditions, increasing to near 100% when taken with food [SPC, 2016]. Absorption of 
rivaroxaban is dependent on the site of its release in the gastrointestinal tract. A 29% and 56% 
decrease in area-under the concentration-time-curve (AUC) and Cmax compared to tablet is reported 
when rivaroxaban granulate is released in the proximal small intestine. Exposure is further reduced 
when rivaroxaban is released in the distal small intestine, or ascending colon [SPC, 2016]. Therefore, 
administration of rivaroxaban distal to the stomach should be avoided since this can result in reduced 
absorption and related rivaroxaban exposure. For patients unable to ingest whole tablets, rivaroxaban 
may be given through a gastric tube after confirmation of the correct placement of the tube. It is 
suggested that the crushed tablet should be administered in a small amount of water via a gastric 
tube after which it should be flushed with water. The dose of rivaroxaban should then be immediately 
followed by enteral feeding [Moore et al., 2014; SPC, 2016].
 
We report our experience of administering rivaroxaban via a PEG tube in three patients requiring oral 
anticoagulation therapy, following a cardioembolic stroke (table 1). A direct oral anticoagulant was 
selected over warfarin in order to reduce the need for regular INR testing in the community and as 
part of a local initiative to decrease district nursing workload. 
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Table 1: Details of the 3 cases who had rivaroxaban administered via a PEG tube, for the secondary 
prevention of stroke in the context of AF 
*calculated using Cockcroft - Gault equation 
** STA-liquid anti-Xa assay® (Diagnostica Stago, France), with appropriate rivaroxaban calibrators 
and controls  
Following ingestion of rivaroxaban, the mean plasma concentrations for the 20mg dose or rivaroxaban 
in the AF population at 3 hours is reported to be 246 ng/mL (5
th
-95
th
 percentile: 172–361) [Mueck et 
al., 2013].  As can be seen from table 1, the concentrations achieved by these patients are 
significantly lower than what one might expect.  
The administration of rivaroxaban via gastric tubes is recommended by the manufacturers of the 
agent, based on work in 55 healthy adults, by Moore and colleagues [2014]. This study reports that 
when rivaroxaban is crushed and administered via a NG tube, a similar relative bioavailability 
 Case 1  Case 2  Case 3  
Gender M M M 
Age 78 85 82 
CHA2DS2Vasc score 5 5 5 
Stroke Left vertebral artery 
occlusion 
left centrum semiovale 
infarct 
Left  middle cerebral 
artery infarct 
Dose 20mg daily 20mg daily 20mg daily 
CrCL (mL/min)* 103 42 62 
Timing of feed PEG feed given 12am to 
5pm, rivaroxaban given 
8.50am (1
st
 level) 
 PEG feed given 1.30pm-
9.30am, rivaroxaban 
given 8.50pm (2
nd
 level) 
Bolus PEG feed regime 
with Fortisip at 8am, 1pm 
and 6pm and Calogen at 
3pm 
Rivaroxaban given at 
6pm 
PEG feed given 12am to 
2pm 
Rivaroxaban given at 
1.40pm  
Rivaroxaban plasma 
concentration** 
(ng/ml) 
Number of doses of 
rivaroxaban recieved 
prior to level 
<20 (14 hours post dose) 
   61 (3 hours post dose) 
14 
64 (3 hours post dose) 
 
8 
76 (3.5 hours post dose) 
 
2 
Outcome Switched to warfarin Switched to apixaban 
and transferred to local 
hospital for rehabilitation 
Switched to apixaban 
with an adequate trough 
concentration achieved 
(65 ng/ml) 
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compared to a whole tablet ingested is achieved. However, a report from Japan, where licensed 
doses of rivaroxaban are lower than those recommended elsewhere world-wide, reports that 
Japanese stroke patients receiving crushed rivaroxaban tablets had significantly lower rivaroxaban 
concentrations, than those stroke patients receiving the whole tablets at the equivalent dose [Okata et 
al., 2014]. 
When tablets are crushed, there is always the possibility that some may be lost in the crushing device, 
adsorbed to the feeding tube and lost in its transfer from the crushing device to the feeding tube. 
Furthermore, rivaroxaban has poor water solubility and does not easily suspend in water, therefore 
making a suitable liquid preparation on the ward environment would be challenging. Our limited 
experience and that from Japan does suggests that significantly lower rivaroxaban concentrations are 
observed, when tablets are crushed and administered by a feeding tube in clinical practice and it 
would be sensible to assay rivaroxaban plasma concentrations when used in scenarios like this.  
Other direct oral anticoagulants, whose absorption is not dependent on food, may result in adequate 
plasma concentrations. . Indeed apixaban’s absorption is not dependent on food and apixaban’s 
manufacturers suggest that following administration of a crushed 5 mg apixaban tablet suspended in 
60 mL of water and delivered via a nasogastric tube, exposure is similar to exposure seen in clinical 
trials involving healthy subjects receiving a single oral 5 mg apixaban tablet dose [SPC, 2016]. 
Switching from rivaroxaban to apixaban was the course of action taken in 2 of the 3 cases presented 
here, with an apixaban plasma concentration being measured in 1 patient and found to be adequate. 
Edoxaban has also shown similar exposure to that seen in healthy subjects receiving a single 60mg 
dose, when crushed, mixed with water and administered via a nasogastric tube [Duchin et al 2017]. 
Dabigatran cannot be administered via gastric tubes due to the significantly increased bioavailability 
of dabigatran if it is administered without the capsule shell. [SPC, 2018].  
In conclusion, if rivaroxaban is administered via a gastric tube, it would be prudent to measure plasma 
concentrations to ensure adequate exposure is being achieved. It may be possible to achieve 
adequate rivaroxaban plasma concentrations when administered via gastric tube providing the 
rivaroxaban SPC instructions are followed to the letter. As our experience has shown this may be 
difficult to achieve in clinical practice. If adequate DOAC concentrations are not achieved through 
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crushing process, then a vitamin K antagonist like warfarin with INR monitoring does remain a suitable 
option. 
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